Search Results - "Courcambeck, Jerome"

  • Showing 1 - 18 results of 18
Refine Results
  1. 1
  2. 2

    GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma by Brun, Sonia, Bassissi, Firas, Serdjebi, Cindy, Novello, Marie, Tracz, Jennifer, Autelitano, François, Guillemot, Marie, Fabre, Philippe, Courcambeck, Jérôme, Ansaldi, Christelle, Raymond, Eric, Halfon, Philipe

    Published in Investigational new drugs (01-12-2019)
    “…Summary Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosomes a potential target…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model by Lagaye, Sylvie, Brun, Sonia, Gaston, Jesintha, Shen, Hong, Stranska, Ruzena, Camus, Claire, Dubray, Clarisse, Rousseau, Géraldine, Massault, Pierre-Philippe, Courcambeck, Jerôme, Bassisi, Firas, Halfon, Philippe, Pol, Stanislas

    Published in World journal of hepatology (28-07-2016)
    “…AIM: To evaluate the antiviral potency of a new antihepatitis C virus(HCV) antiviral agent targeting the cellular autophagy machinery. METHODS: Non-infected…”
    Get full text
    Journal Article
  5. 5

    Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy by Halfon, Philippe, Bourlière, Marc, Khiri, Hacène, Pénaranda, Guillaume, Martineau, Agnes, Oulès, Valérie, Courcambeck, Jérôme, Philibert, Patrick

    Published in AIDS (London) (20-08-2008)
    “…Limited analysis by population sequencing has been reported for the selection of isolates with mutations within the NS3 protease that confer resistance to the…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations by Deval, Jérôme, White, Kirsten L., Miller, Michael D., Parkin, Neil T., Courcambeck, Jérôme, Halfon, Philippe, Selmi, Boulbaba, Boretto, Joëlle, Canard, Bruno

    Published in The Journal of biological chemistry (02-01-2004)
    “…HIV-1 drug resistance mutations are often inversely correlated with viral fitness, which remains poorly described at the molecular level. Some resistance…”
    Get full text
    Journal Article
  8. 8

    Resistance of hepatitis C virus to NS3-4A protease inhibitors : mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations by COURCOMBECK, Jérome, BOUZIDI, Mourad, PERBOST, Regis, JOUIROU, Besma, AMRONI, Nolwenn, CACOUB, Patrice, PEPE, Gérord, SABATIER, Jean-Marc, HOLFON, Philippe

    Published in Antiviral therapy (01-01-2006)
    “…One of the main issues in the development of antiviral therapy is the emergence of drug-resistant viruses. In the case of hepatitis C virus (HCV), selection of…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors by Bondada, Lavanya, Rondla, Ramu, Pradere, Ugo, Liu, Peng, Li, Chengwei, Bobeck, Drew, McBrayer, Tamara, Tharnish, Philip, Courcambeck, Jerome, Halfon, Philippe, Whitaker, Tony, Amblard, Franck, Coats, Steven J., Schinazi, Raymond F.

    Published in Bioorganic & medicinal chemistry letters (01-12-2013)
    “…Herein, we report the synthesis and structure–activity relationship studies of new analogs of boceprevir 1 and telaprevir 2. Introduction of azetidine and…”
    Get full text
    Journal Article
  13. 13

    Synthesis and Antiviral Activity of New Anti-HIV Amprenavir Bioisosteres by Rocheblave, Luc, Bihel, Frédéric, De Michelis, Céline, Priem, Ghislaine, Courcambeck, Jérôme, Bonnet, Brice, Chermann, Jean-Claude, Kraus, Jean-Louis

    Published in Journal of medicinal chemistry (18-07-2002)
    “…Starting from the chemical structure of the recent FDA-approved anti-HIV drug Amprenavir (Agenerase), a potent HIV-protease inhibitor, we have designed new…”
    Get full text
    Journal Article
  14. 14

    Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response by Halfon, Philippe, Khiri, Hacene, Tran, Albert, Pénaranda, Guillaume, Courcambeck, Jerome, Joly, Hélene, Ouzan, Denis

    “…OBJECTIVEAn early virological response has been shown to be predictive of a sustained virological response to antiviral treatment in chronic hepatitis C…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Synthesis and Antiviral Evaluation of Cis-Substituted Cyclohexenyl and Cyclohexanyl Nucleosides by Barral, Karine, Courcambeck, Jérôme, Pèpe, Gérard, Balzarini, Jan, Neyts, Johan, De Clercq, Erik, Camplo, Michel

    Published in Journal of medicinal chemistry (27-01-2005)
    “…Starting from commercially available (rac)-3-cyclohexene-1-carboxylic acid, a series of purine and pyrimidine cis-substituted cyclohexenyl and cyclohexanyl…”
    Get full text
    Journal Article
  18. 18

    Stereoselective synthesis of (3 S,4 S)- tert-butyl- N-Boc-3-ethyl-4-hydroxy- l-prolinate and (3 S,4 R)- tert-butyl- N-Boc-3-ethyl-4-hydroxy- l-prolinate by Chabaud, Pauline, Pèpe, Gérard, Courcambeck, Jérôme, Camplo, Michel

    Published in Tetrahedron (11-04-2005)
    “…Diastereomers of tert-butyl- N-Boc-3-ethyl-4-hydroxy- l-prolinate 1 and 2 have been synthesized in six steps starting from readily available Boc-protected…”
    Get full text
    Journal Article